Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aurora Biosciences (ABSC) -- Ignore unavailable to you. Want to Upgrade?

To: Czechsinthemail who wrote (89)	5/4/1998 2:51:00 PM
From: JZGalt	Read Replies (1) \| Respond to of 359

Am I missing something? I guess I'm missing it also. ;-( FWIW, if I had to put another dime into a biotech, it would be ARQL, not ABSC at this point in time.

To: Czechsinthemail who wrote (89)	5/5/1998 4:54:00 PM
From: Boyce Burge	Respond to of 359

Baird, you have my sympathies. I was a little early on absc, but I think it will turn out alright. Let me illustrate. Lets assume i\that INCY and ABSC are similar pick and shovel biotech companies.... I've taken a look at INCY's chart during the first year it was public (Oct 93-Oct 94). On a split adj. basis it came public at 5, ran up to 7, and then over the next few months moved between 3 and 7 several times... to bottom at 3 in Oct 94... from then on, it went up 80%/year, and the trend line is intact still !!(I look for 66 by year end). So in retrospect perhaps we should have waited 12 months, and let the VCs exit noisly before buying in. My feeling is that ABSC could follow this same kinetics as INCY, but even if everything goes well it may be year's end before we see an uptrend, and we could see 8/sh before then. I sold half at 10, and will think about getting back in if it breaks 12 on good news. Good luck, Boyce

To: Czechsinthemail who wrote (89)	5/6/1998 9:49:00 PM
From: Richard Haugland	Read Replies (3) \| Respond to of 359

I have no real information but I speculate that ABSC might be perceived as having difficulties on delivering what it has promised and this may be of concern to people in the know. I hope this is not true since I am quite long but it could be. Also, in discussions with others, I believe that ABSC has limited by contract the number of companies that it will "play with" and to which it will license its technology other than to approach the entire high-throughput screening market. It may have few if any remaining contracts to announce. Obviously, positive results should help this company, which has very competent scientists and a lot of promise. However, delivering ultra high-throughput screening results may be their challenge and possible downfall. Pthers may know better about the structure and limitations of their agreements.